

Carlos L Arteaga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7598168/publications.pdf>

Version: 2024-02-01

201
papers

27,451
citations

5876

81
h-index

5965

160
g-index

215
all docs

215
docs citations

215
times ranked

30401
citing authors

#	ARTICLE	IF	CITATIONS
1	Metabolic diversity within breast cancer brain-tropic cells determines metastatic fitness. <i>Cell Metabolism</i> , 2022, 34, 90-105.e7.	7.2	33
2	Phase II Study of Copanlisib in Patients With Tumors With <i>PIK3CA</i> Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. <i>Journal of Clinical Oncology</i> , 2022, 40, 1552-1561.	0.8	26
3	Phase II Study of Taselisib in <i>PIK3CA</i> -Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I. <i>JCO Precision Oncology</i> , 2022, 6, e2100424.	1.5	9
4	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2 ⁺ breast cancer. <i>Cancer Research</i> , 2022, 82, GS2-01-GS2-01.	0.4	2
5	Abstract P4-01-02: A spectrum of secondary mutations in <i>HER2</i> augment breast cancer cell growth and reduce neratinib sensitivity in <i>HER2</i> -mutant breast cancer. <i>Cancer Research</i> , 2022, 82, P4-01-02-P4-01-02.	0.4	1
6	Abstract GS3-09: Loss of <i>ASXL1</i> tumor suppressor promotes resistance to CDK4/6 inhibitors in ER+ breast cancer. <i>Cancer Research</i> , 2022, 82, GS3-09-GS3-09.	0.4	1
7	Abstract P5-17-09: A genome-wide CRISPR screen identifies PRMT5 as a novel therapeutic target in ER+/RB1-deficient breast cancer. <i>Cancer Research</i> , 2022, 82, P5-17-09-P5-17-09.	0.4	0
8	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. <i>Cancer Research</i> , 2022, 82, PD2-05-PD2-05.	0.4	2
9	Abstract PD2-01: A platform of CDK4/6 inhibitor-resistant patient-derived breast cancer organoids illuminates mechanisms of resistance and therapeutic vulnerabilities. <i>Cancer Research</i> , 2022, 82, PD2-01-PD2-01.	0.4	1
10	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 942-950.	13.9	220
11	Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer. <i>Cancer Immunology Research</i> , 2022, 10, 829-843.	1.6	12
12	Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress. <i>Nature Cancer</i> , 2022, 3, 866-884.	5.7	8
13	Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS1126-TPS1126.	0.8	2
14	Differential Outcomes in Codon 12/13 and Codon 61 <i>NRAS</i> -Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with <i>NRAS</i> -Mutated Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2996-3004.	3.2	23
15	Metabolic modulation by CDK4/6 inhibitor promotes chemokine-mediated recruitment of T ^H cells into mammary tumors. <i>Cell Reports</i> , 2021, 35, 108944.	2.9	44
16	Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4379-4396.	3.2	30
17	Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity. <i>Cancer Cell</i> , 2021, 39, 1099-1114.e8.	7.7	45
18	Reply to T. Shimoï et al and Y. Shimanuki et al. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01905.	0.8	3

#	ARTICLE	IF	CITATIONS
19	FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188595.	3.3	13
20	TBCRC 032 IB/II Multicenter Study: Molecular Insights to AR Antagonist and PI3K Inhibitor Efficacy in Patients with AR+ Metastatic Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2111-2123.	3.2	91
21	Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1Dâ€”A Subprotocol of the NCI-MATCH (EAY131) Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 214-222.	0.8	106
22	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 120.	2.2	60
23	Dabrafenib and Trametinib in Patients With Tumors With <i>BRAF</i> ^{V600E} Mutations: Results of the NCI-MATCH Trial Subprotocol H. <i>Journal of Clinical Oncology</i> , 2020, 38, 3895-3904.	0.8	145
24	Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer. <i>Nature Communications</i> , 2020, 11, 5488.	5.8	25
25	Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020, 38, 2407-2417.	0.8	102
26	Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers. <i>Cancer Cell</i> , 2020, 37, 183-199.e5.	7.7	33
27	Efficacy and Determinants of Response to HER Kinase Inhibition in <i>HER2</i> -Mutant Metastatic Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 198-213.	7.7	83
28	Overcoming Endocrine Resistance in Breast Cancer. <i>Cancer Cell</i> , 2020, 37, 496-513.	7.7	411
29	TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. <i>Future Oncology</i> , 2020, 16, 705-715.	1.1	62
30	Pooled ctDNA analysis of the MONALEESA (ML) phase III advanced breast cancer (ABC) trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 1009-1009.	0.8	34
31	A versatile oblique plane microscope for large-scale and high-resolution imaging of subcellular dynamics. <i>ELife</i> , 2020, 9, .	2.8	120
32	<i>FGFR1</i> Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 6443-6451.	3.2	54
33	Is Dual mTORC1 and mTORC2 Therapeutic Blockade Clinically Feasible in Cancer?. <i>JAMA Oncology</i> , 2019, 5, 1564.	3.4	19
34	PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer. <i>Npj Breast Cancer</i> , 2019, 5, 31.	2.3	31
35	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apelisisb for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	3.2	76
36	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. <i>Nature Communications</i> , 2019, 10, 1373.	5.8	252

#	ARTICLE	IF	CITATIONS
37	Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors. <i>Cancer Discovery</i> , 2019, 9, 482-491.	7.7	141
38	Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 3971-3988.	2.9	44
39	Exploring Biomarkers of Phosphoinositide 3-Kinase Pathway Activation in the Treatment of Hormone Receptor Positive, Human Epidermal Growth Receptor 2 Negative Advanced Breast Cancer. <i>Oncologist</i> , 2019, 24, 305-312.	1.9	11
40	Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. <i>Breast Cancer Research</i> , 2019, 21, 146.	2.2	52
41	Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4/6 inhibitors against estrogen receptor-positive breast cancers. <i>Breast Cancer Research</i> , 2019, 21, 150.	2.2	14
42	Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 277-289.	3.2	74
43	Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers: Implications to the ExteNET Trial. <i>Clinical Cancer Research</i> , 2019, 25, 771-783.	3.2	29
44	Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3002-3002.	0.8	10
45	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	13.7	572
46	PIK3CA C2 Domain Deletions Hyperactivate Phosphoinositide 3-kinase (PI3K), Generate Oncogene Dependence, and Are Exquisitely Sensitive to PI3K Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 1426-1435.	3.2	27
47	ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors. <i>Clinical Cancer Research</i> , 2018, 24, 2517-2529.	3.2	26
48	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. <i>Oncology</i> , 2018, 7, e1438106.	2.1	54
49	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 127-134.	1.1	90
50	Motivation for Launching a Cancer Metastasis Inhibition (CMI) Program. <i>Targeted Oncology</i> , 2018, 13, 61-68.	1.7	8
51	Unexpected Benefit from Alpelisib and Fulvestrant in a Woman with Highly Pre-treated ER-Positive, HER2-Negative PIK3CA Mutant Metastatic Breast Cancer. <i>Clinical Drug Investigation</i> , 2018, 38, 1071-1075.	1.1	4
52	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. <i>European Journal of Cancer</i> , 2018, 103, 147-154.	1.3	52
53	Neratinib: Inching Up on the Cure Rate of HER2+ Breast Cancer?. <i>Clinical Cancer Research</i> , 2018, 24, 3483-3485.	3.2	6
54	TGF- β 2 signaling promotes tumor vasculature by enhancing the pericyte-endothelium association. <i>BMC Cancer</i> , 2018, 18, 670.	1.1	58

#	ARTICLE	IF	CITATIONS
55	First-line ribociclib (RIB) + letrozole (LET) in hormone receptor-positive (HR+), HER2-negative (HER2 ⁻) advanced breast cancer (ABC): MONALEESA-2 biomarker analyses.. <i>Journal of Clinical Oncology</i> , 2018, 36, 1022-1022.	0.8	15
56	A Phase Ib Study of Alpelisib (BYL719), a PI3K ^{Î±} -Specific Inhibitor, with Letrozole in ER+/HER2 ⁻ Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 26-34.	3.2	268
57	Functional KRAS mutations and a potential role for PI3K/AKT activation in Wilms tumors. <i>Molecular Oncology</i> , 2017, 11, 405-421.	2.1	22
58	An Acquired HER2 ^{T798I} Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant ⁻ Driven Breast Cancer. <i>Cancer Discovery</i> , 2017, 7, 575-585.	7.7	85
59	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2488-2499.	0.4	178
60	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3280-3292.	0.4	76
61	Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery. <i>Cancer Discovery</i> , 2017, 7, 561-574.	7.7	33
62	The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	89
63	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 904-916.	5.1	427
64	HER2-Overexpressing Breast Cancers Amplify FGFR Signaling upon Acquisition of Resistance to Dual Therapeutic Blockade of HER2. <i>Clinical Cancer Research</i> , 2017, 23, 4323-4334.	3.2	64
65	18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials. <i>Clinical Cancer Research</i> , 2017, 23, 3053-3060.	3.2	66
66	Phase Ib Study of Safety and Pharmacokinetics of the PI3K Inhibitor SAR245408 with the HER3-Neutralizing Human Antibody SAR256212 in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 3520-3528.	3.2	19
67	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. <i>Cell Metabolism</i> , 2017, 26, 633-647.e7.	7.2	449
68	An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	29
69	Association of FGFR1 with ER ^{Î±} Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6138-6150.	3.2	94
70	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	91
71	Tumor p38MAPK signaling enhances breast carcinoma vascularization and growth by promoting expression and deposition of pro-tumorigenic factors. <i>Oncotarget</i> , 2017, 8, 61969-61981.	0.8	25
72	The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer. <i>ELife</i> , 2016, 5, .	2.8	100

#	ARTICLE	IF	CITATIONS
73	PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 515-524.	2.7	300
74	Drug response in organoids generated from frozen primary tumor tissues. <i>Scientific Reports</i> , 2016, 6, 18889.	1.6	81
75	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	13.9	1,390
76	Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA H1047R in HER2/ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 457-474.	1.1	13
77	Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence. <i>Science Translational Medicine</i> , 2016, 8, 334ra53.	5.8	105
78	Is There a Future for AKT Inhibitors in the Treatment of Cancer?. <i>Clinical Cancer Research</i> , 2016, 22, 2599-2601.	3.2	38
79	Systematic Prioritization of Druggable Mutations in \sim 45000 Genomes Across 16 Cancer Types Using a Structural Genomics-based Approach. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 642-656.	2.5	43
80	Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population. <i>Cancer Research</i> , 2016, 76, 440-452.	0.4	93
81	RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Clinical Cancer Research</i> , 2016, 22, 1499-1509.	3.2	428
82	The PI3K/AKT Pathway as a Target for Cancer Treatment. <i>Annual Review of Medicine</i> , 2016, 67, 11-28.	5.0	631
83	NCCN Oncology Research Program's Investigator Steering Committee and NCCN Best Practices Committee Molecular Profiling Surveys. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1337-1346.	2.3	23
84	Cardio-Oncology. <i>Circulation</i> , 2015, 132, 2248-2258.	1.6	99
85	Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. <i>Breast Cancer Research</i> , 2015, 17, 148.	2.2	17
86	Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer*. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 1959-1976.	2.5	44
87	Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 ⁺ Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [¹⁸ F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003). <i>Journal of Clinical Oncology</i> , 2015, 33, 2623-2631.	0.8	49
88	Kinome-wide Functional Screen Identifies Role of PLK1 in Hormone-Independent, ER-Positive Breast Cancer. <i>Cancer Research</i> , 2015, 75, 405-414.	0.4	53
89	Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts. <i>Journal of Biomedical Optics</i> , 2015, 20, 026004.	1.4	32
90	Drug-Resistant Brain Metastases: A Role for Pharmacology, Tumor Evolution, and Too-Late Therapy. <i>Cancer Discovery</i> , 2015, 5, 1124-1126.	7.7	5

#	ARTICLE	IF	CITATIONS
91	<i>HER2</i> missense mutations have distinct effects on oncogenic signaling and migration. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6205-14.	3.3	69
92	In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nature Genetics, 2015, 47, 1212-1219.	9.4	139
93	PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. Hematology/ Oncology and Stem Cell Therapy, 2014, 7, 142-148.	0.6	18
94	<i>PIK3CA</i> Activating Mutations: A Discordant Role in Early Versus Advanced Hormone-Dependent Estrogen Receptor-Positive Breast Cancer?. Journal of Clinical Oncology, 2014, 32, 2932-2934.	0.8	32
95	In vivo hyperspectral imaging of microvessel response to trastuzumab treatment in breast cancer xenografts. Biomedical Optics Express, 2014, 5, 2247.	1.5	37
96	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. Cancer Discovery, 2014, 4, 232-245.	7.7	413
97	Emergence of Constitutively Active Estrogen Receptor-Î± Mutations in Pretreated Advanced Estrogen Receptor-Positive Breast Cancer. Clinical Cancer Research, 2014, 20, 1757-1767.	3.2	529
98	Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. Breast Cancer Research, 2014, 16, R9.	2.2	69
99	ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics. Cancer Cell, 2014, 25, 282-303.	7.7	817
100	Quantitative Optical Imaging of Primary Tumor Organoid Metabolism Predicts Drug Response in Breast Cancer. Cancer Research, 2014, 74, 5184-5194.	0.4	251
101	Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel. Oncologist, 2014, 19, 616-622.	1.9	94
102	Characterization of breast cancers with PI3K mutations in an academic practice setting using SNaPshot profiling. Breast Cancer Research and Treatment, 2014, 145, 389-399.	1.1	20
103	Stand Up to Cancer Phase Ib Study of Pan-Phosphoinositide-3-Kinase Inhibitor Buparlisib With Letrozole in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1202-1209.	0.8	159
104	Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer. Oncotarget, 2014, 5, 9049-9064.	0.8	20
105	Phosphatase and Tensin Homolog Deficiency and Resistance to Trastuzumab and Chemotherapy. Journal of Clinical Oncology, 2013, 31, 2073-2075.	0.8	14
106	Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110Î± Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers. Cancer Research, 2013, 73, 6013-6023.	0.4	79
107	Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. Breast Cancer Research, 2013, 15, R55.	2.2	79
108	Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function. Clinical Cancer Research, 2013, 19, 610-619.	3.2	91

#	ARTICLE	IF	CITATIONS
109	Progress in Breast Cancer: Overview. <i>Clinical Cancer Research</i> , 2013, 19, 6353-6359.	3.2	8
110	Conditional Loss of ErbB3 Delays Mammary Gland Hyperplasia Induced by Mutant <i>PIK3CA</i> without Affecting Mammary Tumor Latency, Gene Expression, or Signaling. <i>Cancer Research</i> , 2013, 73, 4075-4085.	0.4	22
111	An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin. <i>Cancer Research</i> , 2013, 73, 6024-6035.	0.4	109
112	Optimal Targeting of HER2-PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical Implications. <i>Cancer Research</i> , 2013, 73, 3817-3820.	0.4	49
113	Mutant <i>PIK3CA</i> accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 14372-14377.	3.3	168
114	Human Breast Cancer Cells Harboring a Gatekeeper T798M Mutation in HER2 Overexpress EGFR Ligands and Are Sensitive to Dual Inhibition of EGFR and HER2. <i>Clinical Cancer Research</i> , 2013, 19, 5390-5401.	3.2	67
115	Trastuzumab-Resistant Cells Rely on a HER2-PI3K-FoxO-Survivin Axis and Are Sensitive to PI3K Inhibitors. <i>Cancer Research</i> , 2013, 73, 1190-1200.	0.4	98
116	TGF- β 2 inhibition enhances chemotherapy action against triple-negative breast cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 1348-1358.	3.9	495
117	Abstract PR05: P-REX1 creates a positive feedback loop to activate growth factor receptor/PI3K signaling. , 2013, , .		0
118	Discordant Cellular Response to Presurgical Letrozole in Bilateral Synchronous ER+ Breast Cancers with a <i>KRAS</i> Mutation or <i>FGFR1</i> Gene Amplification. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2301-2305.	1.9	22
119	Feedback upregulation of HER3 (ErbB3) expression and activity attenuates antitumor effect of PI3K inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 2718-2723.	3.3	313
120	Impact of Genomics on Personalized Cancer Medicine. <i>Clinical Cancer Research</i> , 2012, 18, 612-618.	3.2	52
121	Treatment of HER2-positive breast cancer: current status and future perspectives. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 16-32.	12.5	735
122	HER3 Is Required for HER2-Induced Preneoplastic Changes to the Breast Epithelium and Tumor Formation. <i>Cancer Research</i> , 2012, 72, 2672-2682.	0.4	106
123	Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. <i>Nature Medicine</i> , 2012, 18, 1052-1059.	15.2	219
124	MEK Inhibition Leads to PI3K/AKT Activation by Relieving a Negative Feedback on ERBB Receptors. <i>Cancer Research</i> , 2012, 72, 3228-3237.	0.4	287
125	A Kinome-Wide Screen Identifies the Insulin/IGF-I Receptor Pathway as a Mechanism of Escape from Hormone Dependence in Breast Cancer. <i>Cancer Research</i> , 2011, 71, 6773-6784.	0.4	138
126	ERBB receptors in cancer: signaling from the inside. <i>Breast Cancer Research</i> , 2011, 13, 304.	2.2	7

#	ARTICLE	IF	CITATIONS
127	Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. <i>Breast Cancer Research</i> , 2011, 13, 224.	2.2	365
128	Will PI3K pathway inhibitors be effective as single agents in patients with cancer?. <i>Oncotarget</i> , 2011, 2, 1314-1321.	0.8	49
129	When Tumor Suppressor TGF β 2 Meets the HER2 (ERBB2) Oncogene. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2011, 16, 81-88.	1.0	50
130	Dead-box or black-box: is DDX1 a potential biomarker in breast cancer?. <i>Breast Cancer Research and Treatment</i> , 2011, 127, 65-67.	1.1	12
131	BIM Expression in Treatment-Na \tilde{v} e Cancers Predicts Responsiveness to Kinase Inhibitors. <i>Cancer Discovery</i> , 2011, 1, 352-365.	7.7	268
132	Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers. <i>Cancer Research</i> , 2011, 71, 1871-1882.	0.4	185
133	ER \pm -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer. <i>Cancer Discovery</i> , 2011, 1, 338-351.	7.7	284
134	Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 4452-4461.	0.8	346
135	Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2 \tilde{v} Overexpressing Locally Advanced Breast Cancers. <i>Journal of Clinical Oncology</i> , 2011, 29, 166-173.	0.8	235
136	Why Is This Effective HSP90 Inhibitor Not Being Developed in HER2+ Breast Cancer?. <i>Clinical Cancer Research</i> , 2011, 17, 4919-4921.	3.2	35
137	ErbB3 Ablation Impairs PI3K/Akt-Dependent Mammary Tumorigenesis. <i>Cancer Research</i> , 2011, 71, 3941-3951.	0.4	69
138	New Strategies in HER2-Overexpressing Breast Cancer: Many Combinations of Targeted Drugs Available. <i>Clinical Cancer Research</i> , 2011, 17, 952-958.	3.2	65
139	Resistance to HER2-directed antibodies and tyrosine kinase inhibitors. <i>Cancer Biology and Therapy</i> , 2011, 11, 793-800.	1.5	156
140	A Gene Expression Signature from Human Breast Cancer Cells with Acquired Hormone Independence Identifies MYC as a Mediator of Antiestrogen Resistance. <i>Clinical Cancer Research</i> , 2011, 17, 2024-2034.	3.2	88
141	Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 5021-5026.	3.3	403
142	Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy. <i>Cancer Research</i> , 2010, 70, 299-308.	0.4	182
143	Clinical Development of Phosphatidylinositol-3 Kinase Pathway Inhibitors. <i>Current Topics in Microbiology and Immunology</i> , 2010, 347, 189-208.	0.7	15
144	RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. <i>Breast Cancer Research</i> , 2010, 12, R41.	2.2	63

#	ARTICLE	IF	CITATIONS
145	Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor- α -positive human breast cancer. <i>Journal of Clinical Investigation</i> , 2010, 120, 2406-2413.	3.9	447
146	A Mathematical Model Quantifies Proliferation and Motility Effects of TGF- β 2 on Cancer Cells. <i>Computational and Mathematical Methods in Medicine</i> , 2009, 10, 71-83.	0.7	22
147	ERBB1 and ERBB2 Have Distinct Functions in Tumor Cell Invasion and Intravasation. <i>Clinical Cancer Research</i> , 2009, 15, 3733-3739.	3.2	43
148	Inhibition of Mammalian Target of Rapamycin Is Required for Optimal Antitumor Effect of HER2 Inhibitors against HER2-Overexpressing Cancer Cells. <i>Clinical Cancer Research</i> , 2009, 15, 7266-7276.	3.2	124
149	Transforming Growth Factor β 2 Induces Clustering of HER2 and Integrins by Activating Src-Focal Adhesion Kinase and Receptor Association to the Cytoskeleton. <i>Cancer Research</i> , 2009, 69, 475-482.	0.4	126
150	Ligand-independent phosphorylation of Y869 (Y845) links mutant EGFR signaling to stat-mediated gene expression. <i>Experimental Cell Research</i> , 2008, 314, 413-419.	1.2	23
151	A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 6277-6283.	3.2	69
152	Transforming Growth Factor β 2 Engages TACE and ErbB3 To Activate Phosphatidylinositol-3 Kinase/Akt in ErbB2-Overexpressing Breast Cancer and Desensitizes Cells to Trastuzumab. <i>Molecular and Cellular Biology</i> , 2008, 28, 5605-5620.	1.1	153
153	Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. <i>Journal of Clinical Investigation</i> , 2008, 118, 2609-19.	3.9	443
154	Convergence of p53 and Transforming Growth Factor β 2 (TGF β 2) Signaling on Activating Expression of the Tumor Suppressor Gene maspin in Mammary Epithelial Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 5661-5669.	1.6	37
155	Human Breast Cancer Cells Selected for Resistance to Trastuzumab <i>in vivo</i> Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network. <i>Clinical Cancer Research</i> , 2007, 13, 4909-4919.	3.2	463
156	HER3 and mutant EGFR meet MET. <i>Nature Medicine</i> , 2007, 13, 675-677.	15.2	64
157	Inhibition of TGF- β 2 with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. <i>Journal of Clinical Investigation</i> , 2007, 117, 1305-1313.	3.9	307
158	Inhibition of TGF β 2 signaling in cancer therapy. <i>Current Opinion in Genetics and Development</i> , 2006, 16, 30-37.	1.5	107
159	EGF receptor mutations in lung cancer: From humans to mice and maybe back to humans. <i>Cancer Cell</i> , 2006, 9, 421-423.	7.7	47
160	HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. <i>Cancer Cell</i> , 2006, 10, 25-38.	7.7	426
161	Inhibition of Transforming Growth Factor- β 2 Signaling in Human Cancer: Targeting a Tumor Suppressor Network as a Therapeutic Strategy: Fig. 1.. <i>Clinical Cancer Research</i> , 2006, 12, 4142-4146.	3.2	68
162	Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations. <i>Journal of Biological Chemistry</i> , 2006, 281, 40183-40192.	1.6	85

#	ARTICLE	IF	CITATIONS
163	Association with HSP90 Inhibits Cbl-Mediated Down-regulation of Mutant Epidermal Growth Factor Receptors. <i>Cancer Research</i> , 2006, 66, 6990-6997.	0.4	76
164	Type I Transforming Growth Factor β Receptor Binds to and Activates Phosphatidylinositol 3-Kinase. <i>Journal of Biological Chemistry</i> , 2005, 280, 10870-10876.	1.6	201
165	Conditional Overexpression of Active Transforming Growth Factor β 1 In vivo Accelerates Metastases of Transgenic Mammary Tumors. <i>Cancer Research</i> , 2004, 64, 9002-9011.	0.4	164
166	Overexpression of HER2 (erbB2) in Human Breast Epithelial Cells Unmasks Transforming Growth Factor β -induced Cell Motility. <i>Journal of Biological Chemistry</i> , 2004, 279, 24505-24513.	1.6	144
167	Modeling the cancer patient with genetically engineered mice. <i>Cancer Cell</i> , 2004, 5, 115-120.	7.7	49
168	Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer. <i>Seminars in Oncology</i> , 2004, 31, 3-8.	0.8	38
169	Tyrosine kinase inhibitors. <i>Cancer Cell</i> , 2004, 5, 525-531.	7.7	89
170	Cdk Inhibitor p27Kip1 and Hormone Dependence in Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 368s-371s.	3.2	18
171	Enhancement of Epidermal Growth Factor Receptor-degradation Pathway in Acquired Gefitinib-resistant Human Non-small Cell Lung Cancer Cell Lines. <i>The Showa University Journal of Medical Sciences</i> , 2004, 16, 147-159.	0.1	0
172	Targeting the TGF β 2 signaling network in human neoplasia. <i>Cancer Cell</i> , 2003, 3, 531-536.	7.7	240
173	Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. <i>Oncogene</i> , 2003, 22, 2812-2822.	2.6	449
174	A kinase-inactive type II TGF β 2 receptor impairs BMP signaling in human breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2003, 301, 108-112.	1.0	28
175	ErbB-targeted therapeutic approaches in human cancer. <i>Experimental Cell Research</i> , 2003, 284, 122-130.	1.2	206
176	Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer. <i>Breast Cancer Research</i> , 2003, 5, 96-100.	2.2	48
177	Autocrine Transforming Growth Factor- β 2 Signaling Mediates Smad-independent Motility in Human Cancer Cells. <i>Journal of Biological Chemistry</i> , 2003, 278, 3275-3285.	1.6	148
178	Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β 1. <i>Molecular and Cellular Biology</i> , 2003, 23, 8691-8703.	1.1	190
179	EGF Receptor As a Therapeutic Target: Patient Selection and Mechanisms of Resistance to Receptor-Targeted Drugs. <i>Journal of Clinical Oncology</i> , 2003, 21, 289s-291.	0.8	48
180	Clinical trial design and end points for epidermal growth factor receptor-targeted therapies: implications for drug development and practice. <i>Clinical Cancer Research</i> , 2003, 9, 1579-89.	3.2	63

#	ARTICLE	IF	CITATIONS
181	Targeting HER1/EGFR: a molecular approach to cancer therapy. <i>Seminars in Oncology</i> , 2003, 30, 3-14.	0.8	134
182	Inhibiting tyrosine kinases: successes and limitations. <i>Cancer Biology and Therapy</i> , 2003, 2, S79-83.	1.5	9
183	Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?. <i>Oncologist</i> , 2002, 7, 31-39.	1.9	424
184	ErbB2/Neu-Induced, Cyclin D1-Dependent Transformation Is Accelerated in p27 -Haploinsufficient Mammary Epithelial Cells but Impaired in p27 -Null Cells. <i>Molecular and Cellular Biology</i> , 2002, 22, 2204-2219.	1.1	113
185	Overview of rationale and clinical trials with signal transduction inhibitors in lung cancer. <i>Seminars in Oncology</i> , 2002, 29, 15-26.	0.8	31
186	PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization. <i>Nature Medicine</i> , 2002, 8, 1145-1152.	15.2	729
187	HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer. <i>Seminars in Oncology</i> , 2002, 29, 4-10.	0.8	54
188	Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. <i>Seminars in Oncology</i> , 2002, 29, 3-9.	0.8	232
189	Blockade of TGF- β 2 inhibits mammary tumor cell viability, migration, and metastases. <i>Journal of Clinical Investigation</i> , 2002, 109, 1551-1559.	3.9	402
190	Epidermal Growth Factor Receptor Dependence in Human Tumors: More Than Just Expression?. <i>Oncologist</i> , 2002, 7, 31-39.	1.9	37
191	Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. <i>Cancer Research</i> , 2002, 62, 4132-41.	0.4	471
192	Transforming Growth Factor β 2 Enhances Epithelial Cell Survival via Akt-dependent Regulation of FKHL1. <i>Molecular Biology of the Cell</i> , 2001, 12, 3328-3339.	0.9	175
193	Transforming Growth Factor β 1 Mediates Epithelial to Mesenchymal Transdifferentiation through a RhoA-dependent Mechanism. <i>Molecular Biology of the Cell</i> , 2001, 12, 27-36.	0.9	962
194	Invasion and metastasis of a mammary tumor involves TGF- β signaling. <i>International Journal of Cancer</i> , 2001, 91, 76-82.	2.3	148
195	Cyclin-Dependent Kinase Inhibitor P27Kip1 Is Required for Mouse Mammary Gland Morphogenesis and Function. <i>Journal of Cell Biology</i> , 2001, 153, 917-932.	2.3	75
196	The multifunctional role of transforming growth factor (TGF)- β s on mammary epithelial cell biology. <i>Breast Cancer Research and Treatment</i> , 1996, 38, 49-56.	1.1	41
197	Complex role of tumor cell transforming growth factor (TGF)- β s on breast carcinoma progression. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 1996, 1, 373-380.	1.0	29
198	Growth retardation and tumour inhibition by BRCA1. <i>Nature Genetics</i> , 1996, 12, 298-302.	9.4	359

#	ARTICLE	IF	CITATIONS
199	Reply to "p53 and secreted tumour suppressors". Nature Genetics, 1996, 13, 269-272.	9.4	20
200	Evidence for a positive role of transforming growth factor- β 2 in human breast cancer cell tumorigenesis. Journal of Cellular Biochemistry, 1993, 53, 187-193.	1.2	24
201	Hyperactivation of Torc1 Drives Resistance to the Pan-Her Tyrosine Kinase Inhibitor Neratinib in Her2-Mutant Cancers. SSRN Electronic Journal, 0, , .	0.4	0